--- a
+++ b/clusters/9knumclustersv2/clust_1039.txt
@@ -0,0 +1,45 @@
+Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
+Diabetes mellitus type 
+For Part G: Have type  diabetes mellitus or a history of gestational diabetes mellitus. Participants with a type  diabetes mellitus are eligible if adequate control of blood glucose level is obtained with oral therapy as documented by Hemoglobin Ac <%.
+Patients with controlled Type  diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.
+Type  or Type  diabetes mellitus requiring insulin at study entry
+Patients with controlled type  diabetes mellitus on a stable insulin regimen are eligible
+Participants with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone or participants with controlled Type  diabetes mellitus on a stable insulin regimen may be eligible for this study with approval by the medical monitor
+Uncontrolled diabetes mellitus. Patients with Type II diabetes are eligible if they require only oral hypoglycemic agents and fasting blood glucose level is ?. Patients with Type I diabetes are eligible if their glycosylated hemoglobin (HbAlc) is ?.
+Uncontrolled (per investigator judgment) type I or type II diabetes mellitus.
+Patients with uncontrolled type  diabetes mellitus. If on a stable insulin regimen may be eligible, after discussion with principal investigator.
+History of multiple sclerosis, type  diabetes mellitus (DM) or Guillain-Barre syndrome
+Patients with controlled type  diabetes mellitus on a stable insulin regimen are eligible
+Subjects with uncontrolled type I or II diabetes mellitus
+Type  diabetes mellitus or type  diabetes mellitus actively receiving treatment
+History of autoimmune disease except treated/stable hypothyroidism, Type  diabetes mellitus, and protocol-specified dermatologic conditions
+Patient with an established diagnosis of diabetes mellitus type I or uncontrolled type II
+Patients with active autoimmune disease, with exceptions of vitiligo, type I diabetes mellitus, hypothyroidism and psoriasis.
+Diabetic patients (type I or II diabetes mellitus) must have baseline hemoglobin (Hb)Ac levels NOT higher than .% at study entry
+For the Diabetes Expansion Cohort - Subjects with known history of type  diabetes\n             mellitus that are well-controlled on a stable dose of oral anti-diabetic agents such\n             as metformin and/or sulfonylureas for  weeks prior to screening.
+For the Diabetes Expansion Cohort - Subjects who have type  diabetes mellitus,\n             maturity onset diabetes of the young, hyperglycemia due to reasons other than type \n             diabetes mellitus.
+History of autoimmune disease except controlled/treated hypothyroidism, type  diabetes mellitus, or certain skin disorders
+Patients with an established diagnosis of diabetes mellitus type I or not controlled type II
+Subjects with uncontrolled type I or type II diabetes mellitus (defined as HgbAc > ).
+Type  or Type  diabetes mellitus requiring anti-hyperglycemic medications
+history of Diabetes Mellitus, type  or type ,
+Patients with controlled Type  diabetes mellitus on a stable insulin regimen may be eligible.
+Type I or II diabetes mellitus with HbAc > .% at Screening.
+Known history of autoimmune disease (with the exceptions of medically-controlled hypothyroidism and type I diabetes mellitus)
+Patients with type II diabetes mellitus that is well controlled by dietary measures alone and have a hemoglobin Ac (HgAc) < % are eligible to participate; patients found to have a fasting glucose >=  mmol/L (>=  mg/dL) or glycosylated hemoglobin > % ( mmol/mol) at screening should be assessed for appropriate management according to local policy; those in whom dietary measures alone provide good diabetic control will be eligible for inclusion; type I or II diabetes mellitus requiring either insulin or oral hypoglycemics for routine management will be excluded
+History of type I diabetes mellitus; if a patient has type II diabetes, they must have a hemoglobin (hemoglobin AC) =< %; patients with a screening fasting glucose >  mg/dL will be excluded
+Previously diagnosed diabetes mellitus Type I. Subjects with Type II diabetes are allowed if entry criteria are fulfilled
+Patients with controlled Type  diabetes mellitus on a stable insulin regimen may be eligible.
+Type I or II diabetes mellitus with HbAc > .% at screening (modified by amendment )
+Patient with type  diabetes mellitus or not adequately controlled type  diabetes mellitus
+Subject has Type  Diabetes Mellitus or Type  Diabetes Mellitus and currently being treated with insulin or sulfonylureas.
+DONOR: History of type I or type II diabetes mellitus
+Subjects with type  or type  diabetes mellitus
+Diabetes mellitus, unless it is type II diabetes adequately controlled with anti-diabetic agents (Ac < )
+Type  or  diabetes mellitus
+History of Type I or Type II diabetes mellitus requiring insulin
+History of Type  or  diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents) or fasting glucose ? mg/dL at the prestudy visit. If a diabetic cohort is enrolled, only subjects with a medical history of controlled Type  or  diabetes mellitus will be enrolled in the cohort.
+Patients with a known history of type  or type  diabetes mellitus
+Diagnosis of diabetes mellitus type 
+Type I diabetes mellitus
+History of autoimmune disease. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and patients with controlled type  diabetes mellitus on a stable insulin regimen may be eligible for this study.